PMID: 12797345Jun 12, 2003Paper

Bacillus anthracis

Nursing
Barbara Sheff

Abstract

No abstract listed.

Citations

Nov 19, 2010·Pediatric Dermatology·Sinan AkbayramAhmet Faik Oner
Apr 20, 2010·Journal of Microbiological Methods·Shilpakala Sainath RaoChintamani D Atreya
Feb 6, 2004·Molecular Microbiology·Stephen CendrowskiPhilip Hanna
Jun 5, 2008·Protein Science : a Publication of the Protein Society·Cecilia CarnrotStaffan Eriksson
Mar 21, 2012·Molecular Microbiology·Shandee D DixonPhilip C Hanna
Sep 30, 2006·The International Journal of Biochemistry & Cell Biology·Lixin Xu, David M Frucht
Jul 19, 2006·Microbial Pathogenesis·Jason E ComerAshok K Chopra
Dec 20, 2007·Oral and Maxillofacial Surgery Clinics of North America·Sidney L Bourgeois, Michael J Doherty
Dec 11, 2003·Dental Clinics of North America·Salvador FloresLee Shackelford
Oct 28, 2003·The American Journal of Pathology·Stephen W Chensue
Jun 20, 2014·Biochemical and Biophysical Research Communications·Dionysios J VourtsisGeorgios A Spyroulias

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anthrax

Anthrax toxin, comprising protective antigen, lethal factor, and oedema factor, is the major virulence factor of Bacillus anthracis, an agent that causes high mortality in humans and animals. Here is the latest research on Anthrax.

Anthrax Vaccines (ASM)

Three different types of anthrax vaccines are available; a live-attenuated, an alum-precipitated cell-free filtrate and a protein recombinant vaccine. The effectiveness between the three is uncertain, but the live-attenuated have shown to reduce the risk of anthrax with low adverse events. Here is the latest research on anthrax vaccines.

Anthrax Vaccines

Three different types of anthrax vaccines are available; a live-attenuated, an alum-precipitated cell-free filtrate and a protein recombinant vaccine. The effectiveness between the three is uncertain, but the live-attenuated have shown to reduce the risk of anthrax with low adverse events. Here is the latest research on anthrax vaccines.